These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 23839181)

  • 1. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
    Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
    J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
    Jackson JM; Fowler J; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M;
    J Drugs Dermatol; 2014 Jun; 13(6):699-704. PubMed ID: 24918560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
    Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
    Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
    Moore A; Kempers S; Murakawa G; Weiss J; Tauscher A; Swinyer L; Liu H; Leoni M
    J Drugs Dermatol; 2014 Jan; 13(1):56-61. PubMed ID: 24385120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
    Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
    Gold LS; Papp K; Lynde C; Lain E; Gooderham M; Johnson S; Kerrouche N
    J Drugs Dermatol; 2017 Sep; 16(9):909-916. PubMed ID: 28915286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
    Benkali K; Leoni M; Rony F; Bouer R; Fernando A; Graeber M; Wagner N
    Br J Dermatol; 2014 Jul; 171(1):162-9. PubMed ID: 24506775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MIRVASO (brimonidine tartrate) topical gel 0.33%.
    Abramovits W; Prato A; Vincent KD; Scheinfeld N; Gupta AK
    Skinmed; 2014; 12(1):41-3. PubMed ID: 24720083
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
    Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
    J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
    Urban J; Siripunvarapon AH; Meekings A; Kalowitz A; Markowitz O
    J Drugs Dermatol; 2014 Jul; 13(7):821-6. PubMed ID: 25007365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial.
    Elewski BE; Fleischer AB; Pariser DM
    Arch Dermatol; 2003 Nov; 139(11):1444-50. PubMed ID: 14623704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy.
    Thiboutot DM; Fleischer AB; Del Rosso JQ; Rich P
    J Drugs Dermatol; 2009 Jul; 8(7):639-48. PubMed ID: 19588640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies.
    Stein L; Kircik L; Fowler J; Tan J; Draelos Z; Fleischer A; Appell M; Steinhoff M; Lynde C; Liu H; Jacovella J
    J Drugs Dermatol; 2014 Mar; 13(3):316-23. PubMed ID: 24595578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, randomized, vehicle-controlled clinical trial of once-daily benzoyl peroxide/clindamycin topical gel in the treatment of patients with moderate to severe rosacea.
    Breneman D; Savin R; VandePol C; Vamvakias G; Levy S; Leyden J
    Int J Dermatol; 2004 May; 43(5):381-7. PubMed ID: 15117375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled, pilot study to assess the efficacy and safety of clindamycin 1.2% and tretinoin 0.025% combination gel for the treatment of acne rosacea over 12 weeks.
    Chang AL; Alora-Palli M; Lima XT; Chang TC; Cheng C; Chung CM; Amir O; Kimball AB
    J Drugs Dermatol; 2012 Mar; 11(3):333-9. PubMed ID: 22395584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema.
    Fowler J; Tan J; Jackson JM; Meadows K; Jones T; Jarratt M; Leoni M;
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):474-81. PubMed ID: 25074756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
    Tong LX; Moore AY
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.
    Chu CY
    J Eur Acad Dermatol Venereol; 2007 Apr; 21(4):484-90. PubMed ID: 17373975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%.
    Routt ET; Levitt JO
    J Am Acad Dermatol; 2014 Feb; 70(2):e37-8. PubMed ID: 24438976
    [No Abstract]   [Full Text] [Related]  

  • 20. Erythema of Rosacea: Validation of Patient's Self-Assessment Grading Scale.
    Tan J; Leoni M
    J Drugs Dermatol; 2015 Aug; 14(8):841-4. PubMed ID: 26267728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.